All News

Covid lung pneumonia corona (keep)

Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C)

d Jack Cush, MD

A nationwide cohort study of patients with multisystem inflammatory syndrome in children (MIS-C), a life-threatening complication of COVID-19 infection, showed that many had severe disease during the acute phase, but most recovered quickly and had a reassuring midterm prognosis.

Read Article
OP.Osteoporosis.bone_.jpg

Screening for Osteoporosis to Prevent Fractures - USPSTF Recommendations

d Jack Cush, MD

The US Preventive Services Task Force (USPSTF) has done a systematic review on osteoporosis screening to prevent fractures and put forth its recent recommendations.

Read Article
PMR,flag

BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica

d Jack Cush, MD

Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).

Read Article
tree-736888_640.jpg

2024 In Memorium

d Jack Cush, MD

Sadly, in 2024, Rheumatology lost many of our greatest brethren, mentors, do-gooders and clinicians. These clinicians were responsible for the care of hundreds of thousands with MSK problems, while driving the scientific advances that will shape the lives of millions in the future. They did the painstakingly hard work of caring for the most complex patients and did so with zeal, wonder and love for their patients. Remember them, honor them, and invoke their names and memories frequently as they are the foundation upon which we rheumatologists stand.

Read Article
DM.sine_.jpg

Dazukibart Effective in Adults with Dermatomyositis

d Jack Cush, MD

Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).

Read Article
CDC/ACIP 2025 new Immunization recommendations w/ new vaccine recs for COVID-19, influenza, meningococcal serogroup B, pneumococcal, & RSV. Influenza vaccines have been changed from the quadrivalent to trivalent formulations. https://t.co/Kh1NXMuhVU https://t.co/CRq87PZ31j

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Acute Neck & Back Pain Acute onset febrile, polyarthritis, neck and low back pain Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/2GqyqXAjbF https://t.co/vIeqdHyayV

Links:

Dr. John Cush RheumNow ( View Tweet)
2024 In Memorium Sadly, in 2024, Rheumatology lost many of our greatest brethren, mentors, do-gooders and clinicians. These clinicians were responsible for the care of hundreds of thousands with MSK problems, while driving the scientific advances that will shape the lives of… https://t.co/c8xvPyXbft https://t.co/TEQihNmZnr
Dr. John Cush RheumNow ( View Tweet)
🚨 RheumNow Live 2025: Redefining Rheumatology 🚨 Join top experts & innovators shaping the future of rheumatology care! 💡 Cutting-edge research, interactive sessions, expert insights, & exclusive access await. Be part of the change. Register now! 👉 https://t.co/AQbd7NC2wz… https://t.co/AcmKxGBLvb https://t.co/QlZoAhm8h8

Links:

Dr. John Cush RheumNow ( View Tweet)
Among SLE pts, males have a higher risk of infection compared to females. Males have a (6X) higher prevalence of pneumonia and women have more urinary tract infections. Retrospective study of 119 SLE pts (107 females, 12 males) https://t.co/M12G7hT340 https://t.co/SG7eSGzpXh

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - CREST or More? Is this CREST or Diffuse PSS? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/eA1GijHiYu https://t.co/3EmN9WAyIR

Links:

Dr. John Cush RheumNow ( View Tweet)
Dazukibart Effective in Adults with Dermatomyositis Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/WwvAhPuoGV https://t.co/M0yECxsvcr
Dr. John Cush RheumNow ( View Tweet)
Eltrombopag, a Potential New Treatment for ITP A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP). https://t.co/hYSAEKOjq5 https://t.co/QzBNA3SWVo

Links:

Dr. John Cush RheumNow ( View Tweet)
Pan American Health Org announces that in 2024 saw largest dengue epidemic in the Americas, >12.6 million cases reported (3x record in 2023); 21,000 severe w/ 7,700 deaths; 90% from Argentina, Brazil, Colombia, Mexico. Most USA cases (FL, HI, TX, AZ, CA) seen in travelers… https://t.co/nhuJIP9Y8v https://t.co/QLju8uRKZ8
Dr. John Cush RheumNow ( View Tweet)
Alive in 2025 (1.10.2025) Dr. Jack Cush brings in the new year with a review of the latest from RheumNow. https://t.co/Cw94fF5nFi https://t.co/6c3Gl6GOCY

Links:

Dr. John Cush RheumNow ( View Tweet)
SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%. https://t.co/d8RfXBFUSS https://t.co/Fq1qkfo1NM

Links:

Dr. John Cush RheumNow ( View Tweet)
Just published, a new review of Axial spondyloarthritis from Baraliakos, et al in Lancet! https://t.co/AuMTLo8iQO https://t.co/1icGoXKfB9

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/UMrunimVv6 https://t.co/yZNdnAWCy2

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Overlap Syndrome with ILD How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis? https://t.co/4RyV1zkphe https://t.co/qTZ4JYlJmW

Links:

Dr. John Cush RheumNow ( View Tweet)
VA (Veterans) study of 531 RA-ILD (among 9,701 incident RA) vs 68,852 matched controls - finds exposure to fire smoke PM2.5 assoc w/ RA-ILD/aOR 1.98 (but not RA). NOx, ozone, and PM10 assoc w/ seroneg. RA risk (aOR 1.16-1.25) . Pollution increases risk of RA & RA-ILD… https://t.co/AuG4rRtx4r https://t.co/XyHtjrSfhi
Dr. John Cush RheumNow ( View Tweet)
×